High glucose levels could serve as a biomarker indicating a worse outcome in patients who have experienced their first acute myocardial infarction, according to researchers in Brazil. The… read more.
Researchers report that patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) have achieved a 78% reduced risk of death and a 44% reduced risk of major… read more.
Only 1 in 7 online stock photo images of blood pressure monitoring correctly show how blood pressure should be measured, contributing to potentially inaccurate readings at home and… read more.
Digitoxin reduced the risk of a composite of all-cause death and hospitalisation for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF),… read more.
Adding the novel medication baxdrostat to standard care may help manage high blood pressure and delay the progression of kidney disease in people with chronic kidney disease and… read more.
Abbott announced it has received CE Mark in Europe for an expanded indication for the company’s Navitor transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic,… read more.
Worldwide, 60 million people suffer from heart failure (HF). Heart failure with preserved ejection fraction (HFpEF) is the most common form of HF, especially among people with obesity… read more.
A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of… read more.
Novo Nordisk presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain…. read more.
Researchers report that few people in the USA use salt substitutes to help control high blood pressure despite the fact they are a simple and effective method to… read more.
New research has found that the use of GLP-1 receptor agonists*, a class of medications commonly prescribed for patients with obesity and diabetes, reduces the environmental footprint of… read more.
Idorsia Ltd announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the management of systemic… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
